Advertisement
Mergers and Acquisitions
Subscribe to Mergers and Acquisitions

The Lead

Meda to Acquire Rottapharm

July 31, 2014 8:14 am | News | Comments

Meda announced today that it has entered into a definitive agreement to acquire Rottapharm/Madaus, an Italian company owned by the Rovati family, for a consideration of SEK 21.2 billion on a cash and debt free basis.      

AstraZeneca to Acquire Almirall's Respiratory Disease Business

July 30, 2014 8:11 am | News | Comments

AstraZeneca today announced that it has entered an agreement to transfer to the company the...

Baxter to Sell Commercial Vaccines Business to Pfizer

July 30, 2014 8:06 am | News | Comments

Baxter International has entered into a definitive agreement to sell its two commercially...

PaxVax Acquires FDA-Approved Typhoid Vaccine Vivotif

July 28, 2014 9:19 am | News | Comments

PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that...

View Sample

FREE Email Newsletter

Valeant Takes Allergan Complaints to Regulators

July 21, 2014 8:23 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International Inc. is complaining to regulators that Botox maker and acquisition target Allergan has been making false statements about its business.             

Teva Completes Acquisition of Labrys

July 21, 2014 8:15 am | News | Comments

The acquisition of Labrys brings to Teva LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), which is currently in Phase IIb clinical trials for prevention of chronic and episodic migraine.  

GTCR to Acquire Cole-Parmer Instrument Company

July 17, 2014 1:55 pm | News | Comments

GTCR, a private equity firm, has entered into a definitive agreement to acquire the Cole-Parmer Instrument Company from Thermo Fisher Scientific Inc. for $480 million. Cole-Parmer, headquartered in Vernon Hills, Illinois, is a global manufacturer and distributor of specialty laboratory equipment, instruments and supplies to a diverse range of industries.

Advertisement

Pfizer to Acquire InnoPharma

July 16, 2014 9:34 am | News | Comments

Pfizer and InnoPharma, a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma. Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.

Chiltern Acquires Ockham - Companies Merge Operations

July 15, 2014 11:45 am | News | Comments

Chiltern and Ockham, two full-service contract research organizations (CROs), today announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations. The combined company will be called Chiltern. Ockham's management team will join the management of the enlarged group, thus ensuring a seamless continuation of high quality services.

Anthera Pharmaceuticals Acquires Sollpur for Exocrine Pancreatic Insufficiency From Eli Lilly

July 15, 2014 9:04 am | News | Comments

Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases.   

Mylan to Buy Abbott's Generic Drugs Business in $5.3B Deal

July 14, 2014 8:17 am | News | Comments

Mylan said Monday that the deal will diversify and expand its business outside the U.S. The combined company will be organized in the Netherlands, which will help reduce its tax expenses, while maintaining its headquarters near Pittsburgh.  

AbbVie, Shire Enter Detailed Talks on Combination

July 14, 2014 7:27 am | by The Associated Press | News | Comments

AbbVie and Shire are in detailed talks about a possible combination after AbbVie once again raised the deal price and gave Shire shareholders a bigger stake in the new company. Shire says North Chicago, Illinois-based AbbVie is now offering a cash-stock combination valued at 53.20 British pounds ($91.10) for each share of Shire, which is headquartered on the British island of Jersey.

Advertisement

US to Lead the Megadeal Charge for Second Half of 2014

July 11, 2014 8:52 am | News | Comments

Multi-billion dollar deals across a variety of sectors dominated headlines throughout the first half of 2014, and despite virtually flat US deal volumes rising deal values could be indicative of an M&A rebound to come, according to EY Transaction Advisory Services.

Galderma Finalizes Major Expansion in Aesthetic and Corrective Dermatology in the U.S. and Canada

July 11, 2014 8:13 am | News | Comments

Galderma S.A. announced that it has gained full rights to distribute Restylane, Perlane, Emervel, Sculptra and Dysport from Valeant Pharmaceuticals International, Inc. The expansion into aesthetic and corrective dermatology in the U.S. and Canada completes Galderma's global skin health footprint and extends its leadership in aesthetic medicine worldwide.

More 'Headline-Grabbing' Corporate Deals Expected

July 10, 2014 8:29 am | by PAN PYLAS, Associated Press | News | Comments

More "headline-grabbing" acquisitions are likely over the coming year as businesses take advantage of a period of improving economic growth and cheap financing. That's the conclusion of business consulting firm EY, which says the value of takeover deals announced in the first half of 2014 struck its highest level since the end of the boom years in 2007.

Baxter Acquires AesRx, LLC, Including Its Investigational Sickle Cell Disease Treatment

July 9, 2014 9:08 am | News | Comments

Baxter International Inc. announces the acquisition of AesRx, LLC, a private U.S. biopharmaceutical company focused on orphan drug targets, including the development and commercialization of Aes-103, an investigational prophylactic treatment for sickle cell disease (SCD).

Salix Pharmaceuticals to Combine with Cosmo Technologies to Form Salix Pharmaceuticals, plc

July 9, 2014 8:57 am | News | Comments

Salix Pharmaceuticals, Ltd. and Cosmo Pharmaceuticals S.p.A. announced a definitive merger agreement under which Salix will combine with Cosmo Technologies Limited (“Cosmo Tech”), a subsidiary of Cosmo. Under the terms of the agreement, Salix will become a wholly-owned subsidiary of Irish domiciled Cosmo Tech.

Advertisement

AbbVie Raises its Bid for Shire

July 8, 2014 9:22 am | News | Comments

AbbVie is boosting its offer for Shire by 11 percent to about $51.3 billion, hoping it will be enough to pique the interest of its British counterpart. Shire, known for its rare-disease drugs, has rejected three AbbVie offers to date.   

Pershing Files Documents for Special Meeting Aimed at Ousting Allergan Directors

July 7, 2014 3:05 pm | by The Canadian Press | News | Comments

Pershing Square Capital Management has formally asked Allergan shareholders to support its bid for a special meeting to remove six directors and allow Valeant to proceed with its hostile takeover bid.        

Thoma Bravo to Acquire Sparta Systems

July 7, 2014 8:37 am | News | Comments

Thoma Bravo, LLC, a private equity investment firm, announced that it has entered into an agreement to acquire Sparta Systems, Inc., a global leader in enterprise quality management solutions (EQMS), from current investors Summit Partners and Altaris Capital Partners.

Hospira Completes Acquisition of Orchid's API Manufacturing and R&D Facility

July 7, 2014 8:31 am | News | Comments

Hospira has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd., an Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.

Roche Buying Seragon in U.S. for Up to $1.7B

July 2, 2014 4:29 am | by The Associated Press | News | Comments

Roche Holding AG says its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals, Inc. for up to $1.725 billion in cash and contingency payments.        

Actavis Closes $28B Forest Deal, Names New CEO

July 1, 2014 1:26 pm | by The Associated Press | News | Comments

Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis.                

SP Industries Acquires Bel-Art Products

July 1, 2014 1:16 pm | News | Comments

Through this acquisition, SP, which offers a collection of process and laboratory equipment and specialty glassware, adds to its portfolio over 3,500 additional products sold under Bel-Art’s Scienceware and H-B Instrument brand names.   

Eurofins Buys ViraCor-IBT For $255 Million

July 1, 2014 9:42 am | News | Comments

Ampersand Capital Partners has completed the sale of majority owned portfolio company ViraCor-IBT Laboratories ("VIBT" or "ViraCor") to Eurofins Scientific for $255 million.                         

Pershing Square Settles Lawsuit with Allergan

June 27, 2014 3:28 pm | by The Associated Press | News | Comments

Pershing Square, the investment firm run by activist investor Bill Ackman, said Friday it settled a lawsuit with Allergan, the maker of Botox, related to Allergan's poison pill plan and Pershing's $53 billion offer for the company.   

Auxilium Pharmaceuticals to Merge with Canadian Biotechnology Company QLT

June 26, 2014 8:11 am | News | Comments

Auxilium Pharmaceuticals and QLT Inc. have entered into a definitive agreement under which Auxilium plans to merge with QLT. The transaction is expected to drive shareholder value creation by accelerating Auxilium's ongoing transformation into a leading diversified North American specialty biopharmaceutical company.

Endo to Acquire DAVA Pharmaceuticals

June 25, 2014 9:17 am | News | Comments

Endo International has reached a definitive agreement to acquire DAVA Pharmaceuticals, Inc., a privately-held company specializing in marketed, pre-launch and pipeline generic pharmaceuticals, for $575 million in cash, with additional cash consideration of up to $25 million contingent on the achievement of certain sales milestones. 

IMS Health to Acquire Cegedim’s Information Solutions and CRM Businesses

June 25, 2014 8:07 am | News | Comments

IMS Health, a global provider of information and technology services to the healthcare and life sciences industries, today announced its intention to acquire certain Cegedim information solutions and Customer Relationship Management (CRM) businesses for 385 million euro (approximately $520 million) in cash.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading